Yantai Dongcheng Biochemicals News

Dongcheng Pharmaceutical (002675): A leader in the nuclear medicine industry, innovative assets lead value reshaping

May 28 00:00

Dongcheng Pharmaceutical (002675) Company Brief Review Report: Multiple Factors Influence Short-Term Performance, Steady Progress in Innovative Nuclear Drug Research and Development

May 7 00:00

Dongcheng Pharmaceutical (002675): Heparin API cycle fluctuations and collection affect current performance, nuclear drug innovation and upgrading can be expected in the future

May 6 18:06

Dongcheng Pharmaceutical (002675): Performance fluctuations due to heparin APIs, innovative nuclear drugs are expected to reap

May 5 16:41

Dongcheng Pharmaceutical (002675): Heparin business disrupts performance testing and has a rich layout of nuclear drugs

May 5 00:00

Dongcheng Pharmaceutical (002675): Heparin volume and price has bottomed out and is expected to resume its leading position in the nuclear drug layout in the country

May 4 00:00

Dongcheng Pharmaceutical (002675): Short-term pressure on performance due to heparin APIs, 2024 ushered in a nuclear drug pipeline implementation period

May 1 07:16

Dongcheng Pharmaceutical (002675): Short-term pressure on performance due to heparin APIs, 2024 ushered in a nuclear drug pipeline implementation period

Apr 28 21:01

Research Report Nuggets | Open Source Securities: Maintaining Dongcheng Pharmaceutical's “Buy” Rating, Relevant Products Are Expected to Gradually Implement Subsequent Relevant Products

Gelonghui FinanceNov 17, 2023 17:23

Dongcheng Pharmaceutical (002675): Short-term performance under pressure, innovative nuclear drug research and development continues to advance

Nov 16, 2023 00:00

Dongcheng Pharmaceutical (002675): Increase upstream nuclide supply layout and continue to improve the nuclear drug ecosystem

Nov 15, 2023 08:02

Dongcheng Pharmaceutical (002675): Short-term performance under pressure, rapid clinical progress of nuclear drug products

Nov 8, 2023 00:00

Dongcheng Pharmaceutical (002675): Nuclear drug business is growing steadily, and research and development of innovative diagnostic nuclear drugs is progressing smoothly

Oct 30, 2023 00:00

Dongcheng Pharmaceutical (002675): Under pressure on Q3 performance, it is recommended to focus on the value of nuclear drug innovation drug pipelines

Oct 29, 2023 00:00

Dongcheng Pharmaceutical (002675) 2023 Third Quarter Report Review: Fluctuations in APIs, Short-term performance under pressure, and continuous improvement of the layout of the entire nuclear drug industry chain

Oct 26, 2023 00:00

Dongcheng Pharmaceutical (002675): Steady growth in performance to build a nuclear pharmaceutical ecosystem network throughout the industry chain

天風證券Sep 10, 2023 00:00

Dongcheng Pharmaceutical (002675): Demand for heparin is expected to reach an inflection point, and research and development of innovative nuclear drugs will accelerate

中信證券Sep 5, 2023 18:52

Dongcheng Pharmaceutical (002675): Structured performance is still impressive, business inflection point may reach

德邦證券Aug 29, 2023 09:22

Dongcheng Pharmaceutical (002675): Nuclear drugs resume rapid growth and are optimistic about future development space

廣發證券Aug 27, 2023 00:00

Dongcheng Pharmaceutical (002675): Net profit is in line with expectations, nuclear drug business resumes steady growth

中金公司Aug 25, 2023 18:27